https://www.selleckchem.com/products/tak-901.html
Compared with EGFR-TKIs alone, antiangiogenic agents plus EGFR-TKIs resulted in a higher PFS (hazard ratio, 0.58; 95% confidence interval [CI], 0.50-0.67; P .001). However, no significant differences in OS (hazard ratio, 0.79; 95% CI, 0.53-1.18; P= .26) and ORR (risk ratio, 1.03; 95% CI, 0.97-1.10; P= .3 were found between the 2 groups. An increased risk of serious AEs (risk ratio, 1.41; 95% CI, 1.11-1.79; P= .005) was found in the combination drug therapy group. Antiangiogenic agents plus EGFR-TKIs enhanced PFS for patients with
Like
Comment
Share
